Predict your next investment

Non-Profit Foundation
stanleyresearch.org

See what CB Insights has to offer

Investments

6

Portfolio Exits

3

About Stanley Medical Research Institute

The Stanley Medical Research Institute (SMRI) is a nonprofit organization supporting research on the causes of, and treatments for, schizophrenia and bipolar disorder.

Stanley Medical Research Institute Headquarter Location

9800 Medical Center Suite C-050

Rockville, Maryland, 20850,

United States

301-571-0760

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Stanley Medical Research Institute

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Stanley Medical Research Institute in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Stanley Medical Research Institute News

Inflammatory biomarker may predict depression symptom severity

Dec 7, 2020

Disclosures: Brown reports ongoing or recent research funding from the NIMH; the National Institute on Alcohol Abuse and Alcoholism; the National Institute on Aging; the National Heart, Lung, and Blood Institute; the National Center for Complementary and Integrative Health; the Stanley Medical Research Institute; and Otsuka Pharmaceuticals, as well as serving on an advisory board for Allergan. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio The novel spectroscopic inflammatory biomarker GlycA was positively associated with depression symptom severity, according to study results published in Journal of Clinical Psychiatry. “GlycA is a novel inflammatory biomarker that, currently, is not widely used in clinical practice,” E. Sherwood Brown, MD, PhD, of the department of psychiatry at the University of Texas Southwestern Medical Center, told Healio Psychiatry. “High GlycA levels are associated with medical illnesses, such as heart disease and diabetes. GlycA levels also appear to be more stable over time than high-sensitivity C-reactive protein (hs-CRP). Prior studies had not looked at the association between GlycA and depression.” The investigators obtained data of 3,033 residents of Dallas County, Texas, who were included in The Dallas Heart Study. Participants provided data on depressive symptom severity via the Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR). Brown and colleagues hypothesized that the serum GlycA level would statistically significantly predict QIDS-SR scores after control for demographic covariates. They assessed the association between GlycA level and QIDS-SR scores using multiple linear regression, as well as explored the effect of hs-CRP in predicting QIDS-SR scores. E. Sherwood Brown Results showed GlycA level served as a statistically significant positive predictor of QIDS-SR score with control for age, antidepressant use, sex, ethnicity, smoking status, BMI, drinking status and years of education. GlycA level was not linked to QIDS-SR scores among a subset of adults with moderate-to-severe depression. Further, hs-CRP level did not statistically significantly predict QIDS-SR scores. “Prediction of clinical response to antidepressants using GlycA would be a good next step,” Brown said. “Some studies suggest that hs-CRP levels predict antidepressant response. Our hope would be that inflammatory biomarkers, such as GlycA, may eventually be used to identify subtypes of depression and determine which antidepressant to use. If someone could get a simple blood test that might provide information about the nature of their depression and what antidepressant they might best respond to, then it might be possible to treat the depression more quickly and effectively.”

Stanley Medical Research Institute Investments

6 Investments

Stanley Medical Research Institute has made 6 investments. Their latest investment was in Heptares Therapeutics as part of their Series B on June 6, 2013.

CBI Logo

Stanley Medical Research Institute Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/27/2013

Series B

Heptares Therapeutics

$21M

Yes

5

4/26/2012

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

2/14/2007

Series E

Subscribe to see more

$99M

Subscribe to see more

10

1/9/2004

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/11/2002

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/27/2013

4/26/2012

2/14/2007

1/9/2004

11/11/2002

Round

Series B

Unattributed

Series E

Series B

Series B

Company

Heptares Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$21M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

10

10

10

10

Stanley Medical Research Institute Portfolio Exits

3 Portfolio Exits

Stanley Medical Research Institute has 3 portfolio exits. Their latest portfolio exit was Heptares Therapeutics on February 23, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/23/2015

Acquired

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

2/23/2015

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.